Curis (NASDAQ:CRIS – Get Free Report) is expected to release its earnings data before the market opens on Thursday, February 13th. Analysts expect Curis to post earnings of ($1.36) per share and revenue of $2.04 million for the quarter.
Curis Price Performance
NASDAQ:CRIS opened at $3.51 on Thursday. The company has a market capitalization of $29.72 million, a price-to-earnings ratio of -0.45 and a beta of 3.41. The business has a 50 day moving average of $3.53 and a 200 day moving average of $4.50. Curis has a 1-year low of $2.86 and a 1-year high of $17.49.
Analysts Set New Price Targets
Separately, HC Wainwright restated a “buy” rating and issued a $20.00 price objective on shares of Curis in a report on Tuesday, December 10th.
About Curis
Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.
See Also
- Five stocks we like better than Curis
- What is the Nikkei 225 index?
- 3 Must-Have ETFs Set to Dominate This Quarter
- What does consumer price index measure?
- Seeking Stability? These 3 Stocks Offer Strong Potential
- What is the Shanghai Stock Exchange Composite Index?
- Trade War Bargain Stocks: Top 3 Picks Too Good to Pass Up
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.
